Renal denervation – future or disappointment

Czech version

Authors: T. Mikušová; Z. Stárek; J. Jež; F. Lehar; L. Špinarová
Authors‘ workplace: I. interní kardioangiologická klinika LF MU a FN u sv. Anny v Brně a Mezinárodní centrum klinického výzkumu, Brno
Published in: Kardiol Rev Int Med 2014, 16(1): 34-35
Category: Cardiology Review

Overview

Renal denervation is a novel method in the treatment of resistant hypertension, which is based on selective ablation of sympathetic nervous fibres in the adventitia of renal arteries. The results of randomized, double‑blind trials which would prove efficacy of this method have not been published yet. We will find out in the near future whether this method will be widely indicated for the treatment of hypertension and other diseases associated with increased sympathetic activity, whether renal denervation will be applied only to selected groups of patients, or whether it is a wrong way on the road of human knowledge.

Keywords:
renal denervation – resistant hypertension – autonomic nervous system – sympathetic nervous system

Sources

1. Böhm M, Linz D, Urban D et al. Renal sympathetic denervation: applications in hypertension and beyond. Nat Rev Cardiol. 2013; 10: 465– 476. doi: 10.1038/ nrcardio.2013.89.

2. Ludwig C. De viribus physicis secretionem urinae adjuvantibus. Marburgi Cattorum, typis Elwerti academicis, 1842.

3. Dolezel S. Monoaminergic innervation of the arteries and veins of the kidney observed using fluorescence reaction. Folia Morphol (Praha). 1966; 14: 168– 174.

4. Sobotka PA, Mahfoud F, Schlaich P et al. Sympatho‑renal axis in chronic disease. Clin Res Cardiol. 2011; 100: 1049– 1057. doi: 10.1007/ s00392- 011- 0335- y.

5. Hering D, Esler MD, Krum H et. al. Recent advances in the treatment of hypertension. Expert Rev Cardiovasc Ther 2011; 9: 729– 744. doi: 10.1586/ erc.11.71.

6. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,226 cases. J Am Med Assoc 1953; 152: 1501– 1504.

7. Symplicity HTN- 1 Investigators. Catheter‑based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57: 911– 917. doi: 10.1161/ HYPERTENSIONAHA.110.163014.

8. Krum H, Schlaich MP, Böhm M et al. Percutaneous renal denervation in patients with treatment‑resistant hypertension: final 3‑year report of the Symplicity HTN- 1 study. Lancet 2013; pii: S0140– 6736: 62192- 62193. doi: 10.1016/ S0140– 6736(13)62192– 3.

9. Symplicity HTN-2 Investigators, Esler MD, Krum H,Sobotka PA et al. Renal sympathetic denervation in patients with treatment‑resistant hypertension (The Symplicity HTN- 2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903– 1909. doi: 10.1016/ S0140- 6736(10)62039- 9.

10. Medtronic, Inc. Medtronic Announces U.S. Renal Denervation Pivotal Trial Fails to Meet Primary Efficacy Endpoint While Meeting Primary Safety Endpoint. [online]. Available from: http:/ / www.healthrender.com/ trend/ Medtronic's- U-S- Renal- Denervation- Trial- Fails- To- Meet- Efficacy- Endpoint.